Mealey's (June 5, 2019, 12:20 PM EDT) -- SAN FRANCISCO — A California federal judge on May 10 granted in part and denied in part a motion by drug maker Gilead Sciences Inc. to dismiss a 140-plaintiff complaint that the company knowingly delayed the introduction of a less toxic HIV drug ingredient to preserve sales of earlier versions (Adrian Holley, et al. v. Gilead Sciences, Inc., No. 18-6972, N.D. Calif., 2019 U.S. Dist. LEXIS 79620)....